An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Dermatomyositis is a heterogeneous disease characterized by involvement of the proximal
muscles of the extremities. Some patients have treatment failure or intolerance to the above
treatment regimens, which is called refractory dermatomyositis. Abatacept has been approved
by the FDA for the treatment of three types of rheumatoid immune diseases, and the
international consensus of experts recommends abacepil as a second-line regimen for the
treatment of refractory dermatomyositis based on the evidence of case reports.
Phase:
Early Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University